Click on headlines below to download research

Lonza to make CAR Tregs
TxCell | 12/06/2018

TxCell has announced that Lonza, the biopharmaceutical and cell manufacturing global specialist, will produce its CAR Tregs. TxCell uses a robust manufacturing…

Robust and stable Treg manufacturing
TxCell | 22/02/2018

TxCell has disclosed that it has a viable manufacturing route for its novel CAR Treg products. This uses a stable but low-frequency Treg cell type. The…

Executive interview - TxCell
Executive interview - TxCell | 30/11/2017

TxCell offers a rare investment opportunity as it is the only company applying CAR-T technology to regulatory T-cells (Tregs) for autoimmune and inflammatory…

Humanised CAR Tregs are a key step forward
TxCell | 09/10/2017

TxCell has announced it has a promising humanised CAR-Treg product that can be developed to control graft rejection in solid organ transplant. A trial…

Getting production in order
TxCell | 11/07/2017

TxCell has agreed an important manufacturing supply contract with Lentigen, a German-US producer of the critical lentivirus reagent essential for modifying…

Aiming for first CAR Treg
TxCell | 14/03/2017

TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform continues to develop well. TxCell has four indications in preclinical development…

Exciting CAR opportunities; multiple indications
TxCell | 28/02/2017

TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform is developing well. CAR Tregs offer a powerful and versatile new approach to autoimmune…

Increasing CAR Treg emphasis
TxCell | 09/11/2016

TxCell’s new and novel CAR-modified regulatory T-cell (CAR Treg) platform has developed rapidly since June with three key academic collaborations…

Increasing CAR Treg emphasis
TxCell | 28/10/2016

TxCell’s new and novel CAR-modified regulatory T-cell (CAR Treg) platform has developed rapidly since June with three key academic collaborations…